The Efficacy of Pegylated Liposomal Doxorubicin-Based Neoadjuvant Chemotherapy in Breast Cancer: A Retrospective Case-Control Study in Taiwan

Table 4

Laboratory measurements for adverse effects monitoring reported in PLD and epirubicin groups.

Measurements	Total (n = 366)		PLD (n = 183)		Epirubicin (n = 183)
	N	(%)	N	(%)	n	(%)
Leukocytes (μL)							0.606
≥3500	208	(59.8)	105	(60.3)	103	(59.2)
≥3000–3500	56	(16.1)	31	(17.8)	25	(14.4)
≥2000–3000	69	(19.8)	33	(19.0)	36	(20.7)
≥1000–2000	13	(3.7)	4	(2.3)	9	(5.2)
<1000	2	(0.6)	1	(0.6)	1	(0.6)
Absolute neutrophil count (mm^3)							0.510
≥2000	192	(55.2)	95	(54.6)	97	(55.7)
≥1500–2000	82	(23.6)	44	(25.3)	38	(21.8)
≥1000–1500	48	(13.8)	26	(14.9)	22	(12.6)
≥500–1000	18	(5.2)	6	(3.4)	12	(6.9)
<500	8	(2.3)	3	(1.7)	5	(2.9)
Hemoglobin (g/dl)							<0.001
≥12	62	(17.8)	49	(28.2)	13	(7.5)
≥10–12	195	(56.0)	91	(52.3)	104	(59.8)
≥8–10	76	(21.8)	28	(16.1)	48	(27.6)
≥6.5–8	12	(3.4)	5	(2.9)	7	(4.0)
<6.5	3	(0.9)	1	(0.6)	2	(1.1)
Platelets (μL)							0.644
≥150000	339	(97.4)	169	(97.1)	170	(97.7)
≥50000-75000	6	(1.7)	4	(2.3)	2	(1.1)
≥1000-50000	2	(0.6)	1	(0.6)	1	(0.6)
<10000	1	(0.3)	0	(0.0)	1	(0.6)
AST (U/L)							0.745
≤87.5	324	(93.1)	161	(92.5)	163	(93.7)
>87.5–100	7	(2.0)	3	(1.7)	4	(2.3)
>100–200	13	(3.7)	7	(4.0)	6	(3.4)
>200–800	4	(1.1)	3	(1.7)	1	(0.6)
ALT (U/L)							0.490
≤87.5	294	(84.5)	145	(83.3)	149	(85.6)
>87.5–100	11	(3.2)	8	(4.6)	3	(1.7)
>100–200	32	(9.2)	16	(9.2)	16	(9.2)
>200–800	11	(3.2)	5	(2.9)	6	(3.4)

values are estimated using Fisher’s exact test.